[CAS NO. 1903763-82-5] Sisunatovir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1903763-82-5]

Catalog

HY-123475

Brand

MCE

CAS

1903763-82-5

DESCRIPTION [1903763-82-5]

Overview

MDL	-
Molecular Weight	446.44
Molecular Formula	C23H22F4N4O
SMILES	O=C1C2(C3=C(N1CC4=NC5=C(C=CC(CN)=C5)N4CCCC(F)(F)F)C=C(C=C3)F)CC2

For research use only. We do not sell to patients.

Summary

Sisunatovir (RV521), an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC ₅₀ s of 1.4 nM and 1.0 nM, respectively ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03782662	ReViral Ltd	Respiratory Syncytial Virus Infections	November 6, 2018	Phase 1
NCT03258502	ReViral Ltd	Respiratory Syncytial Virus Infections	July 30, 2017	Phase 2
NCT04267822	ReViral Ltd	RSV Infection\|Stem Cell Transplant Complications\|Lower Resp Tract Infection	June 15, 2020	Phase 2
NCT04065698	ReViral Ltd	Respiratory Syncytial Virus Infections	August 13, 2019	Phase 1
NCT04225897	ReViral Ltd	Respiratory Syncytial Virus (RSV)\|Lower Resp Tract Infection	November 13, 2019	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL ( 56.00 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2399 mL	11.1997 mL	22.3994 mL
5 mM	0.4480 mL	2.2399 mL	4.4799 mL
10 mM	0.2240 mL	1.1200 mL	2.2399 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] DeVincenzo J, et al. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein. Antimicrob Agents Chemother. 2020;64(2):e01884-19